Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study

Bozonnat, A.; Beylot‐Barry, M.; Dereure, O.; D’Incan, M.; Quéreux, G.; Guenova, Emmanuella; Perier‐Muzet, Marie; Dalle, Stéphane; Grange, Florent; Viguier, M.; Ram-Wolff, Caroline; Feldmeyer, Laurence; Beltraminelli, Helmut; Bonnet, Nathalie; Amatore, F.; Maubec, E.; Franck, Nathalie; Machet, L.; Chasset, François; Brunet‐Possenti, F.; Bouaziz, Jean-David; Battistella, Maxime; Donzel, Marie; Pham-Ledard, Anne; Béjar, C.; Moins-Teisserenc, Hélène; Mourah, Samia; Saïag, Philippe; Hainaut, E.; Michel, Catherine; Bens, Guido; Adamski, Henri; Aubin, F.; Boulinguez, Serge; Joly, P.; Tedbirt, Billal; Templier, I.; Troin, L.; Montaudié, Henri; Oro, S.; Faiz, Sarah; Mortier, Laurent; Dobos, Gábor; Bagot, M.; Resche‐Rigon, Matthieu; Montlahuc, Claire; Serret-Larmande, Arnaud; de Masson, Adèle

doi:10.1016/j.eclinm.2024.102679

Public

Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study

Published in EClinicalMedicine • Jun 21, 2024

Authors:

A. Bozonnat

M. Beylot‐Barry

O. Dereure

Abstract

Background: Sézary syndrome is an extremely rare and fatal cutaneous T-cell lymphoma (CTCL). Mogamulizumab, an anti-CCR4 monoclonal antibody, has recently been associated with increased progression-free survival in a randomized clinical trial in CTCL. We aimed to evaluate OS and prognostic factors i...

Subject

Medicine

Brentuximab vedotin

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!